Introduction {#section7-0018720816664824}
============

Medication error is a major patient safety issue in the United States with 1.5 million adverse drug events reported annually, over one third of which occur in the outpatient setting, at an annual estimated cost approaching \$1 billion. Over-the-counter (OTC; i.e., nonprescription) drug use is increasing; almost one half of U.S. adults take at least one OTC medication regularly. Almost one fifth of U.S. adults take acetaminophen in any given week ([@bibr37-0018720816664824]). Acetaminophen overdose is the leading cause of liver failure in the United States, and the package labeling of acetaminophen-containing OTC medications is a likely contributor to many unintentional overdoses ([@bibr36-0018720816664824], [@bibr37-0018720816664824]). A substantial number of medication errors may be related to name confusion due to inadequate labeling on medication packaging. Labeling effectiveness may be influenced by placement of the drug name and dosage strength, undue prominence of company logos compared with drug identifiers, or similar-looking labels or packaging design attributes on different products ([@bibr7-0018720816664824]; [@bibr13-0018720816664824]; [@bibr26-0018720816664824]).

In a recent review, [@bibr28-0018720816664824] found that medication error rates were between 19% and 59% in studies from different countries. Even if many of the errors do not lead to life-threatening situations, such errors are the principle cause of adverse events, especially among the elderly ([@bibr35-0018720816664824]). This user group also elicited the largest number of errors ([@bibr16-0018720816664824]; [@bibr28-0018720816664824]; [@bibr35-0018720816664824]). The elderly population is particularly at risk for consequences of medication errors ([@bibr13-0018720816664824]; [@bibr16-0018720816664824]; [@bibr35-0018720816664824]), because it both uses more medications and is more vulnerable to adverse drug events. According to [@bibr23-0018720816664824], in the United States, 80% of older adults have at least one chronic disease and 50% have two or more, accounting for 75% of health care expenditures. Because elderly users of medication are increasing as the population ages, they are particularly at risk for making medication-related errors.

Of particular concern is the effect of increased use of generic drugs on adherence ([@bibr19-0018720816664824]; [@bibr25-0018720816664824]). In an interview study of 174 Norwegian hypertensive patients, [@bibr19-0018720816664824] found that 5% of the patients used more than one equivalent generic product at the same time. One of the factors identified by the patients as leading to these errors was their belief that the generic drug was an additional drug because they thought the name of the manufacturer was the name of the drug. In a follow-up study, [@bibr20-0018720816664824] found that 10% of a sampled Pakistani population in Oslo, Norway, used two equivalent generic drugs at the same time after the introduction of generic substitution in pharmacies. These findings have been replicated in a study of unintentional overdose with acetaminophen products ([@bibr37-0018720816664824]), whereby 24% of adult users demonstrated that they would overdose and 46% would take a "double dose" of two identical generic products.

Existing recommendations for the optimal design of medication labels are based on expertise and sound human-centered design principles. These recommendations include how and where to print the drug name, placement and prominence of company logos, and use of tall letters to support name discrimination ([@bibr4-0018720816664824]; [@bibr7-0018720816664824]; [@bibr9-0018720816664824]; [@bibr14-0018720816664824]; [@bibr15-0018720816664824]; [@bibr16-0018720816664824]; [@bibr22-0018720816664824]; [@bibr24-0018720816664824]; [@bibr34-0018720816664824]; [@bibr37-0018720816664824]; [@bibr38-0018720816664824]). However, as [@bibr13-0018720816664824] state, there is little empirical evidence to support these recommendations. We set out to provide empirical support for the use of substance name and dose as the main source of information and for more consistent placement of this information. On our redesigned packaging, this information was placed in the upper right corner of the packages (see [Figure 1B](#fig1-0018720816664824){ref-type="fig"} for examples) to avoid confusion with brand names and other proprietary information and in line with human factors studies using eye tracking to identify optimal information placement ([@bibr2-0018720816664824]; [@bibr31-0018720816664824]).

![(A) Example of original (left) and redesigned (right) packages. (B) A trial consisted of a reference image, a fixation cross, and the target image. By pressing a key, participants indicated whether the target image contained the same or a different active ingredient as the reference image.](10.1177_0018720816664824-fig1){#fig1-0018720816664824}

To compare the redesigned packages with the original packages, we wanted to provide a task that took into account both mental effort and the fact that medication packages might be viewed from different angles relative to the users. We chose a modified version of the [@bibr32-0018720816664824] mental rotation task (MRT). The MRT has been used to evaluate a range of design issues in human-centered design ([@bibr1-0018720816664824]; [@bibr6-0018720816664824]; [@bibr11-0018720816664824]; [@bibr21-0018720816664824]). The MRT is a well-established example of a recognition working-memory task that allows manipulation of mental workload ([@bibr6-0018720816664824]). Because users may have varying degrees of cognitive resources available when trying to recognize medication packaging, the MRT appears to be an effective way to evaluate medication package recognition. In addition, given that medication packages are usually either held or placed at different angles, the visual frame through which they are evaluated will change similar to the MRT task.

Since color can be a source of confusion ([@bibr8-0018720816664824]; [@bibr10-0018720816664824]), we wanted to test the robustness of the proposed design principles in situations with confusing color schemes. We sought to test the robustness of the suggested design for errors related to color confusion (i.e., the same color scheme used on different medications, leading users to believe they are in fact the same substance). We therefore included a color factor with two levels: same- and different-colored packages.

We also wanted to test the robustness of the design with regard to age-related challenges. Age is associated with decreased capabilities that are important for identifying and recognizing the correct medication, for instance, reduced working-memory performance, attention, speed of information processing, and inhibitory control ([@bibr18-0018720816664824]). In addition, both vision and perceptual function in general decline with age ([@bibr5-0018720816664824]) and can interact with attentional resources in such a way that elderly users might perform worse than might be expected from reduced cognitive function alone. For recognition tasks, age is related to lower visual accuracy and longer reaction times ([@bibr27-0018720816664824]). Because it is important to know whether design changes that reduce errors for young users may also do so for elderly users, we included a group of users older than 70 years.

We studied three drug package manipulations---standardized placement of information, light background, and highlighted substance name---in a task requiring a decision between brand- and generic-named medications. On the basis of the literature, we predict that the proposed design will lead to faster and more accurate identification of medications in both elderly and young users. Second, we predict that both the use of substance name and its placement will affect discrimination. Finally, we predict that the redesigned packages will be less prone to being misread due to age and color confusion.

Experiment 1 {#section8-0018720816664824}
============

Method {#section9-0018720816664824}
------

### Participants {#section10-0018720816664824}

Fifty-nine volunteers (38 female) within two age groups were recruited and compensated to participate in this study, including 30 elderly users (69--86 years, mean 75.9; 20 females) and 29 young students (18--38 years, mean 25.9; 18 females). Each gave written informed consent in accordance with protocols approved by the University of Oslo, Norway. The participants were interviewed regarding their use of substances. The participants in the elderly group used on average 3.1 drugs, whereas the students used 0.5 different drugs. This research complied with the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board at Department of Psychology, University of Oslo.

### Materials {#section11-0018720816664824}

Images of 20 pharmaceutical packages with the original design and 20 packages with a manipulated design were created with a Canon camera (see example in [Figure 1](#fig1-0018720816664824){ref-type="fig"}). The redesigned packages were made using Adobe Photoshop CS2. We inserted a white rectangle (occupying 25% of the front) in the upper right-hand corner of the package. Here we displayed the name of the active ingredient (Arial bold 24-point font size) and dose (using Arial bold 18-point font size). On some small packages, the fonts were reduced proportionally. The brand names were reduced to 60% of original size.

### Design {#section12-0018720816664824}

Participants were presented with an MRT, a classic cognitive test used to measure recognition and discrimination performance in individuals. We used an adapted version of the original MRT task described by Shepard and Metzler in 1971 ([@bibr29-0018720816664824]; [@bibr30-0018720816664824]; [@bibr33-0018720816664824]; [@bibr32-0018720816664824]).

We used packages in two versions, one with original names, labels, and colors (original) and one with our redesigned information placement (redesigned). In addition, we created versions of the packages with new colors to enable a factorial measure of the same substance with same (non-interfering) or different (interfering) color as well as different substance with same (interfering) and different (non-interfering) color.

### Procedure {#section13-0018720816664824}

The elderly participants were recruited from senior citizens' day centers. The testing was done in a laboratory setting. The participants signed a consent form and were shown the packages on laptop computer screens positioned at a comfortable distance in front of participants. They were shown examples of the task and did a brief training session before they completed the 720 trials divided into two sessions.

In each trial, we presented a Picture A (reference image) for 1 s, followed by a fixation cross for 1 s, and finally, a Picture B (target image) for 1 s ([Figure 1](#fig1-0018720816664824){ref-type="fig"}). The participants were allowed to reply within an intertrial interval of 3 s.

The pictures were viewed from about 70 cm on a white background. The drug packages were presented in the center of the display. The second picture was presented at rotations of 0°, 60°, 120°, or 180°.

In each trial, the participants had to indicate as quickly as possible whether the two packages contained the same active ingredient. By pressing a green (same) or red (different) key on the computer keyboard, participants placed each index finger on one key and had a reaction time cutoff of 3 s.

### Data analysis {#section14-0018720816664824}

Data analysis was performed with SPSS v19. The experimental conditions age (young, elderly), design (original, redesigned), and substance (same, different) were applied in a mixed within- and between-group analysis. To correct for multiple comparisons, Bonferroni-corrected post hoc analysis with a cutoff of .05 was used.

Only reaction times for correct responses were included in the analysis. Because of known age-related effects on reaction time performance of MRTs ([@bibr12-0018720816664824]), we calculated slope and intercept of reaction times to avoid confounds. Although there was no effect of age on reaction time slope, there was a significant difference in intercept (elderly, *M* = 1,053 ms; young, *M* = 740), *F*(1, 57) = 43.966, *p* \< .001, η^2^ = .440. Intercept correlated moderately with the mean reaction times (*r*^2^ ranging from .41 to .55) and was included in the analysis as a covariate in the reaction time analysis.

Results {#section15-0018720816664824}
=======

Reaction times {#section16-0018720816664824}
--------------

We performed a 3 × 2 repeated-measures analysis of reaction times using the intercept of the MRT as covariate. A significant main effect of age, *F*(1, 57) = 54.594, *p* \< .001, η^2^ = .494; design, *F*(1, 57) = 75.834, *p* \< .001, η^2^ = .575; and substance, *F*(1, 57) = 46.725, *p* \< .001, η^2^ = .455, was found. In addition, a significant two-way interaction was found between design and substance, *F*(1, 57) = 13.247, *p* \< .001, η^2^ = .191 (see [Table 1](#table1-0018720816664824){ref-type="table"}). These interaction effects were due to a significantly larger difference between redesigned and original packages when the substances were the same compared with packages with different substances.

###### 

Mean Reaction Times, Accuracy, Standard Errors, and Confidence Intervals (CI) for the Different Versions of Packages

![](10.1177_0018720816664824-table1)

                                    Young       Elderly                                      
  --------------------------------- ----------- --------------- ----------- ---------------- ------------------------------------------------------------
  Reaction time in milliseconds                                                              
   Original same substance          981 (37)    \[907, 1055\]   1282 (35)   \[1212, 1352\]   [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Original different substance     1036 (42)   \[951, 1121\]   1344 (36)   \[1273, 1416\]   [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Redesigned same substance        779 (33)    \[713, 844\]    1152 (31)   \[1090, 1214\]   [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Redesigned different substance   894 (38)    \[819, 970\]    1318 (40)   \[1237, 1398\]   [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
  Accuracy in percentages                                                                    
   Original same substance          65 (4)      \[56, 73\]      44 (3)      \[38, 50\]       [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Original different substance     95 (1)      \[94, 96\]      77 (4)      \[69, 84\]       [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Redesigned same substance        92 (2)      \[89, 96\]      85 (2)      \[81, 90\]       [\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}
   Redesigned different substance   95 (1)      \[93, 96\]      78 (3)      \[71, 85\]       [\*\*\*](#table-fn1-0018720816664824){ref-type="table-fn"}

*p* ≤ .05. \*\**p* ≤ .01. \*\*\**p* ≤ .001.

Accuracy {#section17-0018720816664824}
--------

To compare the redesigned and original packages, we performed a two-way repeated MANOVA with design, substance, and age group as factors. We found a main effect of design, *F*(1, 57) = 223.659, *p* \< .001, η^2^ = .795; an interaction between design and substance, *F*(1, 57) = 171.205, *p* \< .001, η^2^ = .750; a main effect of age, *F*(1, 57) = 42.094, *p* \< .001, η^2^ = .425; and an interaction between design, substance, and age, *F*(1, 57) = 4.988, *p* = .029, η^2^ = .080 (see [Figure 2](#fig2-0018720816664824){ref-type="fig"}). These effects were due to a significant difference between redesigned and original packages when substance was the same (see [Table 1](#table1-0018720816664824){ref-type="table"} for confidence intervals for all the conditions) both for elderly and young subjects.

![(A) Overall percentage correct responses for the two designs for the young group. (B) Overall percentage correct responses for the two designs for the elderly group.](10.1177_0018720816664824-fig2){#fig2-0018720816664824}

There was no significant difference between the groups for redesigned packages in this condition.

As discussed previously, a prominent contributor to adverse drug events is when a patient erroneously takes a generic drug containing the same substance as one he or she already takes ("double dipping"). To test the extent of the double-dipping error, we analyzed the errors in the condition where the packages contained the same substance as the reference sample. This method allowed for comparison of identical packages versus packages with the same substance but different brand.

In separate 2 × 2 MANOVAs, a significant two-way interaction between design and brand was found in both age groups: elderly, *F*(1, 29) = 110.104, *p* \< .001, η^2^ = .792; young, *F*(1, 27) = 27.000, *p* \< .001, η^2^ = .691. The effect was due to a significant difference between redesigned and original packages when packages were generic and non-identical brands.

For the packages with different substances, only an effect of age was found, *F*(1, 57) = 21.784, *p* \< .001, η^2^ = .276, with elderly users making more errors than younger users.

Color {#section18-0018720816664824}
-----

There are two conditions in which color can create confusion. The first is when two packages contain the same substance but have different color schemes. This design may lead users to the erroneous conclusion that the packages contain two different substances. The second is when two packages contain different substances but the packages have a similar color scheme, leading the users to the erroneously believe that the packages contain the same substance. We tested whether the redesigned packages made such color-induced errors more or less likely when comparing different generic medications. A Package Design × Color × Age repeated-measures analysis for both color contexts showed that in the different-substance condition, a significant effect of age was found, *F*(1, 57) = 20.611, *p* \< .001, η^2^ = .266 ([Table 2](#table2-0018720816664824){ref-type="table"}), but no significant effect of design.

###### 

Error Rates in Percentages for the Original and Redesigned Packages When Users Matched Different Substances With Same or Different Color Schemes in Generic Medications

![](10.1177_0018720816664824-table2)

                    Young    Elderly                            
  ----------------- -------- ------------ -------- ------------ ------------------------------------------------------------
  Different color                                               
   Redesigned       6 (1)    \[4, 8\]     24 (4)   \[16, 32\]   [\*\*\*](#table-fn3-0018720816664824){ref-type="table-fn"}
   Original         5 (1)    \[4, 7\]     25 (4)   \[17, 33\]   [\*\*\*](#table-fn3-0018720816664824){ref-type="table-fn"}
  Same color                                                    
   Redesigned       9 (2)    \[5, 13\]    19 (2)   \[14, 24\]   [\*\*](#table-fn3-0018720816664824){ref-type="table-fn"}
   Original         44 (5)   \[34, 54\]   69 (4)   \[61, 76\]   [\*](#table-fn3-0018720816664824){ref-type="table-fn"}

*Note*. CI = confidence interval.

*p* ≤ .05. \*\**p* ≤ .01. \*\*\**p* ≤ .001.

For the same-substance and different-color conditions, there was a main effect of age, *F*(1, 57) = 20.400, *p* \< .001, η^2^ = .264; and design, *F*(1, 57) = 206.220, *p* \< .001, η^2^ = .783; and a significant interaction between age and design, *F*(1, 57) = 6.183, *p* = .016, η^2^ = .098 ([Table 2](#table2-0018720816664824){ref-type="table"}). The interaction effect was due to a significantly greater difference between redesigned and original packages for the elderly group.

The results point to color as an important source of confusion when two packages contain the same substance but are colored differently. Especially, elderly users erroneously conclude that the packages contain two different substances, which suggests that color might contribute to the "double-dipping" problem. Even though the redesigned packages seem to be more robust, elderly users made significantly more errors related to color than did the young users.

Discussion {#section19-0018720816664824}
==========

Our main findings indicate that there are advantages related to both effort (reaction times) and accuracy for the redesigned packages in the MRT. However, since we highlighted the substance name with a prominent font, provided a distinct contrast background, and standardized placement of this information in Experiment 1, we cannot discern the role of these three manipulations. We therefore designed a follow-up experiment whereby we manipulated placement and contrast background for the same subset of packages as in Experiment 1. The main findings in Experiment 1 pointed to main effects of age and age interactions related to decrease in performance. The elderly performed worse in all the conditions. However, there were no interactions indicating a different pattern of errors in the two groups. We therefore chose to do the second experiment only with a group of young users.

Experiment 2 {#section20-0018720816664824}
============

Participants {#section21-0018720816664824}
------------

Twenty-five volunteers (13 female), all young students (21--28 years, mean 25.9), participated in the study. Each gave written consent in accordance with protocols approved by the University of Oslo, Norway. The participants were interviewed regarding their use of substances (0.6 different drugs).

Materials {#section22-0018720816664824}
---------

The same materials were used as in Experiment 1. In the package-redesigned condition, the packages were identical to those used in Experiment 1 (see [Figure 3](#fig3-0018720816664824){ref-type="fig"}). In the placement condition, we constructed a version of the redesigned packages with the white field and substance names placed in the lower left corner. In the third condition, the transparent condition, we prepared another set of packages with identical substance names positioned in the standard place (upper right corner) but with the original (not redesigned) color background.

![(A) Example of the three conditions: redesigned (top), placement (middle), and transparent (bottom). (B) The same trial procedure was used as in Experiment 1.](10.1177_0018720816664824-fig3){#fig3-0018720816664824}

Design {#section23-0018720816664824}
------

The Experiment 1 task was used. Experiment 2 had three conditions. In the redesigned condition, we used the same packages as in Experiment 1. In the transparent condition, substance names were placed in the upper right corner but without the contrasted background. In the placement condition, we used the same design as in the redesigned condition but randomly placed the critical information in either the upper right or the lower left corner of the packages.

Procedure {#section24-0018720816664824}
---------

The procedure was identical to Experiment 1.

Analysis {#section25-0018720816664824}
--------

The same statistical procedures were followed as in Experiment 1.

Results {#section26-0018720816664824}
=======

Reaction times {#section27-0018720816664824}
--------------

A repeated-measures MANOVA showed a significant main effect, *F*(2, 48) = 15.803, *p* \< .001, η^2^ = .397 (see [Table 3](#table3-0018720816664824){ref-type="table"}). The effects were due to a significantly longer reaction time for the transparent condition compared with the others. There were no differences between the redesigned and placement conditions.

###### 

Mean Reaction Times in Milliseconds, Errors in Percentages, Standard Errors, and Confidence Intervals (CI) for the Different Conditions

![](10.1177_0018720816664824-table3)

               Reaction Time   Errors                    
  ------------ --------------- ---------------- -------- -----------
  Redesigned   1017 (40)       \[934, 1100\]    6 (1)    \[4, 8\]
  Substance    1131 (47)       \[1035, 1227\]   12 (2)   \[8, 15\]
  Placement    1035 (50)       \[932, 1138\]    7 (1)    \[5, 9\]

Accuracy {#section28-0018720816664824}
--------

A repeated-measures MANOVA showed a significant main effect, *F*(2, 48) = 5.925, *p* = .005, η^2^ = .198 (see [Table 3](#table3-0018720816664824){ref-type="table"}). The effects were due to more errors for the transparent condition compared with the other two conditions. The redesigned and placement conditions were not significantly different (*p* = .590).

Discussion {#section29-0018720816664824}
==========

There was a high rate of recognition error for generic medication in their original package designs. The most prominent error was to wrongly assume that the medication packages contained different substances when in fact they contained the same substance (elderly, 55%, and young, 35%). In addition, this type of error increased to 68% (elderly) and 43% (young) when the packages had different colors. Our experiment was done in an artificial experimental context and cannot predict the incidence of these types of medication errors in the real world. However, our results are consistent with documented field trials ([@bibr37-0018720816664824]). In a review of articles published between 1990 and 2014, [@bibr28-0018720816664824] found that the incidence of medication errors was between 19% and 59% and that the elderly users made more errors than young users. Incorrect dosage, forgetting or mixing up medications, failing to recall, and taking out-of-date and inappropriately stored drugs were common home use medication errors. In our study, we tested errors related to recognition and perception of packages. Our findings suggest that perceptual recognition error can also be a factor in erroneous comparison of medication in real life.

Several studies have pointed to age as a factor in adverse medication usage, supporting our finding of significant age-related effects both on reaction time and errors. As [@bibr27-0018720816664824] point out, the elderly are a vulnerable group due to higher risk of perceptual errors, a greater use of medication, and a greater risk of adverse effects of medication errors. It is therefore crucial to ensure that the probability of error is as low as possible.

In our study, highlighting substance name by providing a clear contrast band background for the name and dose and positioning this information in a dedicated place on the packages help users identify substances in generic packages faster and more accurately. The results of Experiment 2 suggest that the key to error reduction in the redesigned packages is the highlighted substance name placed in a high-contrast area (band or box). Randomizing the placement of this information on packages had less impact on reaction times or errors.

Our package redesign was based on general human factors guidelines. This study is, as far as we know, the first experimental test of those principles. One study by [@bibr17-0018720816664824] made a similar test program for package labels. The labels were redesigned in several versions following the Food and Drug Administration industry guidance for labeling and packaging ([@bibr3-0018720816664824]). In that study, the alternate label designs included a three-dimensional tablet image; in addition, a color band highlighting the dosage strength increased contrast between the text, color bands, and the paper substrate. In a study with seven test users, they found that this alternate label led to fewer medication errors. In contrast to our study, they did not find any differences between the different designs related to reaction time or errors in reading brand name and dosage. Gerhart et al. performed realistic user testing in a pharmaceutical environment but did not manipulate substance name or packaging in their study; only the medication labels were changed. Brand and dosage were their focal parameters; they studied the effect of a redesign only on pharmacists in a prescription-writing task, not on patients. Even so, their results match well with ours, indicating that highlighting of substance name and dose might be a key design factor in reducing medication errors.

Our study has some limitations. It was performed under controlled experimental conditions, and the MRT, although relevant for some aspects of medication recognition, is not a direct simulation of every aspect of users' handling of medication. Environmental factors, such as lighting conditions, and package design principles, such as tactile information and manipulation of package size, were not addressed in our experiments.

Despite these limitations, several aspects of our results are notable. First, because we used packages as they actually occur on the market as a control, the relative difference in recognition error suggests that our results might be relevant for more ecologically relevant contexts. Second, we manipulated two key variables that challenge the recommended design principles: package color and placement of substance name.

Color is a controversial topic in medication packaging design, and no unified recommendations exist on how to avoid confusion and reduce errors ([@bibr8-0018720816664824]). We did not set out to test explicitly the effect of color coding. Instead, we did test two possible causes of confusion. The first is when two packages contain the same substance but have different color schemes, which leads the users to erroneously conclude that the packages contain two different substances. We observed a dramatic improvement in this type of error for both user groups (from 69% to 19% for the elderly and 44% to 9% for the young) with the redesigned packages compared with original generic medications. There might be a perceptual component to these types of errors in addition to the known effects of motivation, lack of understanding of consequences, and misunderstandings of prescriptions. Thus it is the confusion between two identical medications that provides highest error rates with the original design. As noted by [@bibr37-0018720816664824], this is the type of error that is most prominent in overdose or "double dipping" and is therefore an extremely important factor to counter.

The second confusion type is when two packages contain different substances but the packages have similar color schemes, leadings users to erroneously conclude that the packages contain the same substance. In this case, the error rates with both original and redesigned packaging were smaller, and there was no difference between the original and redesigned packages. However, the elderly users produced more errors than the young users (elderly, 24%, and young, 5%). Because there was no significant difference between the two error types for the redesigned packages within user groups, these error rates might be a task-specific floor effect related to mental rotation. However, this finding should not be interpreted as a measure of expected medication errors in a real-life setting.

In our second experiment, we found that highlighting the substance name and dosage information improved reaction time and reduced errors. In contrast, displaying key information in a predictable place on the packages did not seem to be as important as highlighting it. This finding is in accordance with the [@bibr17-0018720816664824] study, wherein dosage strength was highlighted in a similar way as in our experiment. It is plausible that giving a prominent place to substance name and dose with a band of high-contrast color might be the key to better recognition of active substance in medications. We did not include elderly users in this experiment and therefore cannot rule out the possibility that the substance name placement might be more important for this group. Given the general effect of age, further studies of medication packaging design should include elderly users.

Age is a major concern for usage of OTC medications. As [@bibr27-0018720816664824] point out, older patients' age means poorer cognitive states, greater number of medicines used, and increase in errors made. Our findings point in the same direction. Even corrected for age-related task effects, the elderly users were significantly more prone to error. The package redesign reduced performance differences between elderly and young users significantly. Because elderly use more strategies to perform the MRT (Dror et al., 2005), highlighting key information may better support more global strategies associated with age. To further investigate these assumptions, controlled field trials need to be preformed. The combination of field and laboratory experiments allows translation of sound human factors principles to evidence-based guidance ([@bibr13-0018720816664824]).

Conclusion {#section30-0018720816664824}
==========

A redesign of generic medication packages decreased recognition errors. The most prominent improvement occurred when users might be predisposed to believe that the packages contained two different substances when in fact they contained the same substance. The key factor in the redesigned packages was the highlighting of active substance name and dose on medication packages on a high-contrast background. These findings are consistent with design principles that guide perceptual recognition. The present study provides important insights into the understanding of the perceptual aspects of medication package design and suggests that minor changes in packaging design significantly improves users' ability to determine whether or not two different drugs contain the same active ingredient. Ecological field trials can provide insight into the importance of the suggested design changes relative to other causes of medication error.

Key Points {#section31-0018720816664824}
==========

Elderly users make more mistakes recognizing generic medication than young users.The most prominent error was to wrongly assume that the matched and sample packages contained different substances (elderly, 55%, and young, 35%) when in fact they contained the same substance.Color confusion increased this type of error to 68% (elderly) and 43% (young) when package coloring indicated different medications.Redesign of packages with highlighted substance name on a high-contrast box or band significantly reduced this type of error.
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